New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2013
08:48 EDTCLDXCelldex announces CDX-301 combination study 'positive' results
Celldex Therapeutics announces "positive" results from a preclinical combination study of CDX-301 and Mozobil demonstrating that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice. The data support future clinical development of CDX-301 and demonstrate a potent cell mobilization regimen combining CDX-301 and Mozobil, which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation. The company said, "We plan to initiate a pilot clinical study evaluating CDX-301 alone and in combination with Mozobil in the transplant setting in early 2014 and look forward to seeing how this program progresses."
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
14:02 EDTCLDXCelldex Phase 1 study of CDX-1401 demonstrates robust antibody response
Subscribe for More Information
April 15, 2014
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 7, 2014
16:02 EDTCLDXCelldex says CDX-014 to enter clinical development
Celldex Therapeutics reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate that targets the protein TIM-1. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015," said Tibor Keler, senior VP and Chief Scientific Officer of Celldex.
April 4, 2014
09:50 EDTCLDXCelldex management to meet with Guggenheim
Meetings to be held in New York on April 10-11 hosted by Guggenheim.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use